Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026)
Johnson & Johnson (JNJ) posted Non-Current Debt of $37.3 billion for Q2 2026, little changed sequentially from $37.5 billion in Q1 2026, and down 4.82% YoY from $39.2 billion in Q2 2025.
Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Non-Current Debt for 18 years, with the latest figure at $37.3 billion in Q2 2026.
- Quarterly Non-Current Debt fell 4.82% year-over-year to $37.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.3 billion (down 4.82% YoY) and the FY2025 annual result came in at $39.4 billion, up 21.72% from the prior year.
- Non-Current Debt steadied at $37.3 billion in Q2 2026 per JNJ's latest filing, from $37.5 billion in the prior quarter.
- Over five years, Non-Current Debt peaked at $39.4 billion in Q4 2025 and troughed at $25.1 billion in Q1 2024.
- A 5-year average of $32.6 billion and a median of $32.1 billion in 2022 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt dropped 28.19% in 2024, then soared 52.92% in 2025.
- Over 5 years, Non-Current Debt stood at $27.6 billion in 2022, then slipped by 0.92% to $27.4 billion in 2023, then gained by 18.46% to $32.4 billion in 2024, then gained by 21.72% to $39.4 billion in 2025, then declined by 5.31% to $37.3 billion in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $37.3 billion, $37.5 billion, and $39.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.45 Bn | 631.70 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 469.14 Bn | 462.57 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 381.04 Bn | 373.90 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 301.58 Bn | 293.89 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.69 Bn | 252.79 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 236.91 Bn | 222.92 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 182.62 Bn | 179.44 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 161.28 Bn | 149.58 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.81 Bn | 101.64 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 54.98 Bn | 47.60 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 37.34 Bn |
| Mar 29, 2026 | 37.53 Bn |
| Dec 28, 2025 | 39.44 Bn |
| Sep 28, 2025 | 39.41 Bn |
| Jun 29, 2025 | 39.24 Bn |
| Mar 30, 2025 | 38.36 Bn |
| Dec 29, 2024 | 32.40 Bn |
| Sep 29, 2024 | 31.29 Bn |
| Jun 30, 2024 | 31.64 Bn |
| Mar 31, 2024 | 25.08 Bn |
| Dec 31, 2023 | 27.35 Bn |
| Oct 1, 2023 | 26.05 Bn |
| Jul 2, 2023 | 33.90 Bn |
| Apr 2, 2023 | 34.93 Bn |
| Jan 1, 2023 | 28.44 Bn |
| Oct 2, 2022 | 27.60 Bn |
| Jul 3, 2022 | 28.29 Bn |
| Apr 3, 2022 | 28.85 Bn |
| Jan 2, 2022 | 32.12 Bn |
| Oct 3, 2021 | 30.13 Bn |